These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 32959246)
41. Recent advancements in combination subunit vaccine development. Tan M; Jiang X Hum Vaccin Immunother; 2017 Jan; 13(1):180-185. PubMed ID: 27649319 [TBL] [Abstract][Full Text] [Related]
42. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100 [TBL] [Abstract][Full Text] [Related]
43. Direct Cloning of Bacterial Surface Polysaccharide Gene Cluster for One-Step Production of Glycoconjugate Vaccine. Ma Z; Zhang H; Li L; Chen M; Wang PG ACS Infect Dis; 2019 Jan; 5(1):74-78. PubMed ID: 30445812 [TBL] [Abstract][Full Text] [Related]
44. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned. Eto Y; Saubi N; Ferrer P; Joseph J AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327 [TBL] [Abstract][Full Text] [Related]
45. Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae. Li L; Sun C; Yang F; Yang S; Feng X; Gu J; Han W; Langford PR; Lei L Vaccine; 2013 Oct; 31(45):5269-75. PubMed ID: 24051157 [TBL] [Abstract][Full Text] [Related]
46. Evaluation of Virus-Like Particle-Based Tumor-Associated Carbohydrate Immunogen in a Mouse Tumor Model. Sungsuwan S; Wu X; Huang X Methods Enzymol; 2017; 597():359-376. PubMed ID: 28935111 [TBL] [Abstract][Full Text] [Related]
47. Progress in developing virus-like particle influenza vaccines. Quan FS; Lee YT; Kim KH; Kim MC; Kang SM Expert Rev Vaccines; 2016 Oct; 15(10):1281-93. PubMed ID: 27058302 [TBL] [Abstract][Full Text] [Related]
48. Developments in virus-like particle-based vaccines for HIV. Buonaguro L; Tagliamonte M; Visciano ML; Tornesello ML; Buonaguro FM Expert Rev Vaccines; 2013 Feb; 12(2):119-27. PubMed ID: 23414404 [TBL] [Abstract][Full Text] [Related]
49. Virus-like particle-display of the enterotoxigenic Escherichia coli heat-stable toxoid STh-A14T elicits neutralizing antibodies in mice. Govasli ML; Diaz Y; Puntervoll P Vaccine; 2019 Oct; 37(43):6405-6414. PubMed ID: 31515145 [TBL] [Abstract][Full Text] [Related]
50. Carriers and Antigens: New Developments in Glycoconjugate Vaccines. van der Put RMF; Metz B; Pieters RJ Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851097 [TBL] [Abstract][Full Text] [Related]
51. Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques. Weiwei G; Xuexing Z; Chong W; Yongkun Z; Qi W; Hualei W; Gary W; Ying X; Haijun W; Zengguo C; Na F; Hang C; Tiecheng W; Yuwei G; Junjie S; Songtao Y; Xianzhu X J Med Virol; 2017 Dec; 89(12):2069-2074. PubMed ID: 28402024 [TBL] [Abstract][Full Text] [Related]
52. Prokaryotic Production of Virus-Like Particle Vaccine of Betanodavirus. Xie J; Huang R; Lai Y Methods Mol Biol; 2016; 1404():211-223. PubMed ID: 27076301 [TBL] [Abstract][Full Text] [Related]
53. Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice. Gai W; Zheng X; Wang C; Wang H; Zhao Y; Wang Q; Wong G; Zhang W; Feng N; Qiu B; Chi H; Li N; Wang T; Gao Y; Shan J; Yang S; Xia X Virol J; 2017 Oct; 14(1):204. PubMed ID: 29070075 [TBL] [Abstract][Full Text] [Related]
54. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli. Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397 [TBL] [Abstract][Full Text] [Related]
55. Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. Terra VS; Mills DC; Yates LE; Abouelhadid S; Cuccui J; Wren BW J Med Microbiol; 2012 Jul; 61(Pt 7):919-926. PubMed ID: 22516134 [TBL] [Abstract][Full Text] [Related]
56. Formulation and stabilization of recombinant protein based virus-like particle vaccines. Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136 [TBL] [Abstract][Full Text] [Related]
57. Characterization of human enterovirus71 virus-like particles used for vaccine antigens. Zhao D; Sun B; Sun S; Fu B; Liu C; Liu D; Chu Y; Ma Y; Bai L; Wu Y; Zhou Y; Su W; Hou A; Cai L; Xu F; Kong W; Jiang C PLoS One; 2017; 12(7):e0181182. PubMed ID: 28732070 [TBL] [Abstract][Full Text] [Related]
58. Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines. Sun X; Stefanetti G; Berti F; Kasper DL Proc Natl Acad Sci U S A; 2019 Jan; 116(1):193-198. PubMed ID: 30510007 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice. Rioux S; Dubreuil D; Bégin C; Laferrière C; Martin D; Jacques M Comp Immunol Microbiol Infect Dis; 1997 Jan; 20(1):63-74. PubMed ID: 9023043 [TBL] [Abstract][Full Text] [Related]
60. Production of Zika Virus Virus-Like Particles. Kuadkitkan A; Ramphan S; Worawichawong S; Sornjai W; Wikan N; Smith DR Methods Mol Biol; 2021; 2183():183-203. PubMed ID: 32959245 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]